A
ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.
Investor insights
Funding rounds participated in
$155M sweet spot round size
Investor type
Privately Held
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Funding rounds raised
Total raised
$155M
from 3 investors over 1 rounds
A
ArriVent Biopharma raised $155M on January 29, 2023
Investors: Sofinnova Investments, General Catalyst and + 15 Other investors